For Companies Seeking to Enter the Japanese Market

Japanese pharmaceutical companies are actively considering the in-licensing of regenerative medicine products that have already been approved overseas or are currently under regulatory review.

We can support introductions and business matching for:

• Gene therapies

• Cell-based therapies

• Hybrid products, including cell–gene and cell–device combinations

We welcome inquiries from companies and organizations seeking to:

• Develop and obtain approval for their products in Japan

• License their products to Japanese pharmaceutical companies

• Identify co-development, commercialization, or distribution partners

• Expand their business opportunities in the Japanese market

Through our network of pharmaceutical companies, biotech ventures, investors, CDMOs, academic institutions, and regulatory experts in Japan, we support strategic partnering and market entry.

Please contact us if you are interested in bringing your regenerative medicine product to Japan.